KCM
PRQR icon

Kynam Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Kynam Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Hold
1,566,317
– – 0.16% 29
2026
Q1 		$2.54M Hold
1,566,317
– – 0.16% 37
2025
Q4 		$3.16M Sell
1,566,317
-83,145
-5% -$194K 0.2% 35
2025
Q3 		$3.51M Hold
1,649,462
– – 0.26% 34
2025
Q2 		$3.36M Sell
1,649,462
-100,538
-6% -$164K 0.36% 27
2025
Q1 		$2.33M Hold
1,750,000
– – 0.2% 30
2024
Q4 		$4.64M Buy
+1,750,000
New +$5.56M 0.27% 26

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Kynam Capital Management's PRQR Position: Q2 2026 in Review

Kynam Capital Management held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 1,566,317 shares worth $2.91M. The position accounts for 0.16% of the portfolio, ranked #29.

Kynam Capital Management first reported a position in PRQR in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.64M in Q4 2024. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Kynam Capital Management held 1,566,317 shares of ProQR Therapeutics worth $2.91M as of Q2 2026.
  • Kynam Capital Management left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up 0.16% of Kynam Capital Management's portfolio in Q2 2026, its #29 holding.
  • Kynam Capital Management first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Kynam Capital Management's ProQR Therapeutics position peaked at $4.64M in Q4 2024.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.